Reading Time: 2 minutesThis week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried
Author: Research Information Team
The MND Association’s vision is a world free from MND. Realising this vision means investing more in research, further developing partnerships with the research community, funding bodies and industry, while ensuring that advances in understanding and treating MND are communicated as quickly and effectively as possible.
Reading Time: 3 minutesAt last year’s International Symposium on ALS/MND in Perth, Australia, Professor Jeffrey Iliff talked about the glymphatic system (C1 in abstract book) – a series
Reading Time: 5 minutesGuest researcher blog post written by Matthew Nolan. My name is Matthew, I’m currently a post-doctoral researcher at Massachusetts General Hospital and Harvard Medical School in
Reading Time: 4 minutesA systematic review of existing scientific literature, performed by a team of researchers led by Dr Arpan Mehta, MRC/MND Association Lady Edith Wolfson Clinical Fellow
Reading Time: 3 minutesGuest researcher blog post written by Darija Šoltić. Originally from Croatia, I came to the UK to do my PhD in neuroscience, where I worked
Reading Time: 3 minutesA recently published paper, reviewing 15 studies that investigated the effectiveness of riluzole as a treatment for MND in real-time, has suggested that the drug
Reading Time: 4 minutesGuest researcher blog post: My name is Sophie Nyberg and I am a neuroscientist currently working in the Lighthouse COVID-19 testing labs in Alderley Park,
Reading Time: 2 minutesGuest researcher blog post written by Elisabeth Jirström: Hi! My name is Elisabeth Jirström and I am a PhD student at Royal College of Surgeons
Reading Time: 6 minutesGuest researcher blog post about the recently published paper on the identification of potential new biomarkers in the blood, in the journal Brain Communications. Written